Lavipharm S.A. (ATH:LAVI)

Market Cap	141.70M
Revenue (ttm)	52.95M
Net Income (ttm)	8.98M
Shares Out	168.69M
EPS (ttm)	0.05
PE Ratio	16.34
Forward PE	n/a
Dividend	0.02 (2.38%)
Ex-Dividend Date	Jul 17, 2025

Volume	286,144
Average Volume	151,482
Open	0.8500
Previous Close	0.8400
Day's Range	0.8190 - 0.8650
52-Week Range	0.6500 - 0.8950
Beta	1.24
RSI	61.13
Earnings Date	Sep 17, 2025

About Lavipharm

Lavipharm S.A. engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, cosmetics, and healthcare products to physicians and pharmacists in Greece and internationally. The company offers pharmaceutical products for cardiology, oncology-urology, central nervous system, chronic pain, and self- treatment. It also provides prescription medicines and over the counter (OTC) products, as well as LIFELAB CBD products. The company was founded in 1911 and is based in Paiania, Greece.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1911
• Employees: 299
• Stock Exchange: Athens Stock Exchange
• Ticker Symbol: LAVI

Financial Performance

In 2024, Lavipharm's revenue was 52.95 million, an increase of 10.68% compared to the previous year's 47.84 million. Earnings were 8.98 million, an increase of 380.06%.